Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Management of Female Menopause

  • Chapter
Endocrine Function and Aging

  • 68 Accesses

Abstract

The climacteric years define that phase in the aging process of women marking the transition from the reproductive stage of life (characterized by regular, ovulatory menstrual cycles) to a stage when the ovary is no longer capable of releasing eggs for fertility and when the ovarian estrogen production falls below the levels that stimulate menses. This transition involves three steps: Premenopause is an interval of months to years during which hormone secretion is erratic and menses are consequently irregular. Menopause is simply the cessation of menses. The date is retrospectively assigned when a woman has been without menstrual flow for one year. Postmenopause is the succeeding years during which symptoms directly or indirectly attributable to the waning ovarian estrogen secretion may or may not appear. By common usage, “menopause” and “menopausal syndrome” have become synonymous with “climacteric” and “climacteric syndrome.”

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jick H, Porter J, Morrison AS. Relation between smoking and age of natural menopause. Lancet 1977;1:1354–1357.

    Article  CAS  PubMed  Google Scholar 

  2. Sherman BM, West JH, Korenman SG. The menopausal transition: Analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976;42:629–636.

    Article  CAS  PubMed  Google Scholar 

  3. Goldenberg RL, Grodin JM, Rodbard D, et al. Gonadotropins in women with amenorrhea: The use of plasma follicle stimulating hormone to differentiate women with and without ovarian follicles. Am J Obstet Gynecol 1973;116:1003–1009.

    CAS  PubMed  Google Scholar 

  4. Schindler AE, Ebert A, Friedrich E. Conversion of androstenedione to estrone by human fat tissue. J Clin Endocrinol Metab 1972;35:627–630.

    Article  CAS  PubMed  Google Scholar 

  5. Naftolin F, Ryan K, Petro Z: Aromatization of androstenedione by the diencephalon. J Clin Endocrinol Metab 1971;33:368–370.

    Article  CAS  PubMed  Google Scholar 

  6. Siiteri PD, MacDonald PC. Role of extraglandular estrogen in human endocrinology. In: Greep RO, Astwood E, eds. Handbook of Physiology: Endocrinology, Vol 2. Washington; American Physiological Society, 1973:615–630.

    Google Scholar 

  7. Casper RF, Yen SSC, Wilkes MM. Menopausal flushes: Neuroendocrine link with pulsatile LH secretion. Science 1979;205:823–825.

    Article  CAS  PubMed  Google Scholar 

  8. Meldrum DR. The pathophysiology of postmenopausal symptoms. Semin Reprod Endocrinol 1983;1:11–17.

    Article  Google Scholar 

  9. Tulandi T, Lai S. Menopausal hot flush. Obstet Gynecol Surv 1985;40:553–563.

    Article  CAS  PubMed  Google Scholar 

  10. Edington RF, Chagnon JP, Steinberg WM. Clonidine (Dixarit) for menopausal flushing. Can Med Assoc J 1980;123:23–26.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Tulandi T, Kinch RA, Guyda H, et al. Effect of methyldopa on menopausal flushes, skin temperature, and luteinizing hormone secretion. Am J Obstet Gynecol 1984; 150:709–712.

    Article  CAS  PubMed  Google Scholar 

  12. Ravnikar VA, Regestein QR, Schiff I. Hormone therapy for menopausal sleep problems? Contemp OB/GYN 1982;20:71–93.

    Google Scholar 

  13. Strickler RC, Borth R, Cecutti A, et al. The role of oestrogen replacement in the climacteric syndrome. Psychol Med 1977;7:631–639.

    Article  CAS  PubMed  Google Scholar 

  14. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153–160.

    Article  CAS  PubMed  Google Scholar 

  15. Rigg LA, Hermann H, Yen SSC. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195–197.

    Article  CAS  PubMed  Google Scholar 

  16. Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133–139.

    Article  CAS  PubMed  Google Scholar 

  17. Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978;92:953–963.

    CAS  PubMed  Google Scholar 

  18. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis: Its clinical features. JAMA 1941;116:2465–2474.

    Article  Google Scholar 

  19. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy. I. A 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979;53:277–281.

    CAS  PubMed  Google Scholar 

  20. Lindsay R: Identification of bone loss and its prevention by sex steroids. Postgrad Med 1987;Sept. 4:13–19.

    Google Scholar 

  21. Riis BJ, Thomsen K, Strom V, et al. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61–65.

    Article  CAS  PubMed  Google Scholar 

  22. Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius. Lancet 1979;2:705–709.

    Article  CAS  PubMed  Google Scholar 

  23. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195–1198.

    Article  CAS  PubMed  Google Scholar 

  24. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319–324.

    Article  CAS  PubMed  Google Scholar 

  25. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759–763.

    CAS  PubMed  Google Scholar 

  26. Lobo RA, McCormick W, Singer F, et al. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1–5.

    CAS  PubMed  Google Scholar 

  27. Michnovicz JJ, Hershcopf RJ, Naganuma H, et al. Increased 2-hydroxylation of estradiol as a possible mechanism for the antiestrogenic effect of cigarette smoking. N Engl J Med 1986;315:1305–1309.

    Article  CAS  PubMed  Google Scholar 

  28. Wren BG, Routledge DA. Blood pressure changes: Oestrogens in climacteric women. Med J Aust 1981;2:528–531.

    PubMed  Google Scholar 

  29. NIH Consensus Development Conference Summary. Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080–2086.

    Article  Google Scholar 

  30. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:365–374.

    Article  Google Scholar 

  31. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977;62: 707–714.

    Article  CAS  PubMed  Google Scholar 

  32. Rosenberg L, Armstrong B, Jick H, et al. Myocardial infarction and estrogen therapy in postmenopausal women. N Engl J Med 1976;294:1256–1259.

    Article  CAS  PubMed  Google Scholar 

  33. Jick H, Dinan B, Rotherman KJ. Noncontraceptive estrogens and nonfatal myocardial infarction. JAMA 1978;239:1407–1408.

    Article  PubMed  Google Scholar 

  34. Jick H, Dinan B, Herman R, et al. Myocardial infarction and other vascular diseases in young women: Role of estrogens and other factors. JAMA 1978;240:2548–2552.

    Article  CAS  PubMed  Google Scholar 

  35. Pfeffer RI, Whipple GH, Kurosaki TT, et al. Coronary risk and estrogen use in postmenopausal women. Am J Epidemiol 1978;107:479–487.

    CAS  PubMed  Google Scholar 

  36. Ross RK, Paganini-Hill A, Mack TM, et al. Menopausal estrogen therapy and protection from death from ischemic heart disease. Lancet 1981;1:858–860.

    Article  CAS  PubMed  Google Scholar 

  37. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment: A pilot case-control study. Br Med J 1981;282:1277–1278.

    Article  Google Scholar 

  38. Bain C, Willett W, Hennekens CH, et al. Use of postmenopausal hormone and risk of myocardial infarction. Circulation 1981;64:42–46.

    Article  CAS  PubMed  Google Scholar 

  39. Szklo M, Tonascia J, Gordis L, et al. Estrogen use and myocardial infarction risk: A case-control study. Prev Med 1984:510–516.

    Google Scholar 

  40. Sullivan JM, Vander Zwaag R, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988;108:358–363.

    Article  CAS  PubMed  Google Scholar 

  41. Gruchow HW, Anderson AJ, Barboriak JJ, et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988;115:954–963.

    Article  CAS  PubMed  Google Scholar 

  42. Burch JC, Byrd BF Jr, Vaughn WK. The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol 1984;118:778–782.

    Google Scholar 

  43. Hammond CB, Jelovsek FR, Lee KL, et al. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979;133:525–536.

    CAS  PubMed  Google Scholar 

  44. Petitti DB, Wingerd J, Pellegrin F, et al. Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979;242: 1150–1154.

    Article  CAS  PubMed  Google Scholar 

  45. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality: Preliminary results from the Lipid Research Clinics Program follow-up study. JAMA 1983;249:903–906.

    Article  CAS  PubMed  Google Scholar 

  46. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: The Framingham Study. N Engl J Med 1985;313:1038–1043.

    Article  PubMed  Google Scholar 

  47. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044–1049.

    Article  CAS  PubMed  Google Scholar 

  48. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek study. Obstet Gynecol 1987;70: 289–293.

    PubMed  Google Scholar 

  49. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105–1110.

    Article  CAS  PubMed  Google Scholar 

  50. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results of the Lipid Research Clinics program followup study. Circulation 1987;75:1102–1109.

    Article  CAS  PubMed  Google Scholar 

  51. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164–1167.

    Article  CAS  PubMed  Google Scholar 

  52. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1164–1167.

    Article  Google Scholar 

  53. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262–1267.

    Article  CAS  PubMed  Google Scholar 

  54. McDonald TW, Annegers JF, O’Fallow WM, et al. Exogenous estrogen and endometrial carcinoma: Case-control and incidence study. Am J Obstet Gynecol 1977; 127:572–580.

    CAS  PubMed  Google Scholar 

  55. Gray LA Sr, Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol 1977;49:385–389.

    PubMed  Google Scholar 

  56. Horwitz RI, Geinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978;299:1089–1094.

    Article  CAS  PubMed  Google Scholar 

  57. Hammond CB, Jelovsek FR, Lee KL, et al. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 1979;133:537–547.

    CAS  PubMed  Google Scholar 

  58. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–79.

    Article  CAS  PubMed  Google Scholar 

  59. Gambrell RD Jr. The menopause: Benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982;37:457–474.

    PubMed  Google Scholar 

  60. Gibbons WE, Moyer DL, Lobo RA, et al. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol 1986;154:456–461.

    Article  CAS  PubMed  Google Scholar 

  61. Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 1982; 27(8 Suppl):539–548.

    CAS  PubMed  Google Scholar 

  62. Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–330.

    CAS  PubMed  Google Scholar 

  63. Kaufman DW, Miller DR, Rosenberg L, et al. Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984;252:63–67.

    Article  CAS  PubMed  Google Scholar 

  64. Wingo PA, Layde PM, Lee NC, et al. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987;257:209–215.

    Article  CAS  PubMed  Google Scholar 

  65. Coulam CB, Annegers JF. Chronic anovulation may increase postmenopausal breast cancer risk. JAMA 1983;249:445–446.

    Article  Google Scholar 

  66. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980;243:1635–1639.

    Article  CAS  PubMed  Google Scholar 

  67. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435–443.

    PubMed  Google Scholar 

  68. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304: 560–563.

    Article  CAS  PubMed  Google Scholar 

  69. Ottosson UB, Johansson BG, Von Schoultz B: Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151:746–750.

    Article  CAS  PubMed  Google Scholar 

  70. Magos AL, Brincat M, Studd JWW, et al. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65:496–499.

    CAS  PubMed  Google Scholar 

  71. Prough SG, Aksel S, Wiebe H, et al. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987;157:1449–1453.

    Article  CAS  PubMed  Google Scholar 

  72. Padwick ML, Endacott J, Whitehead MI. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the mangement of postmenopausal women. Am J Obstet Gynecol 1985;152:1085–1091.

    Article  CAS  PubMed  Google Scholar 

  73. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologie effects of transdermal estradiol. N Engl J Med 1986;314:1615–1620.

    Article  CAS  PubMed  Google Scholar 

  74. Jensen J, Riis BJ, Strom V, et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987;156:66–71.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Ronald C. Strickler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Geriatric Research, Education, and Clinical Center, Veterans Administration Medical Center, St. Louis, Missouri, 63125, USA

    H. James Armbrecht Ph.D. , Rodney M. Coe Ph.D.  & Nirandon Wongsurawat M.D., F.A.C.P. ,  & 

  2. Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, Missouri, 63104, USA

    H. James Armbrecht Ph.D. , Rodney M. Coe Ph.D.  & Nirandon Wongsurawat M.D., F.A.C.P. ,  & 

  3. Department of Biochemistry, St. Louis University School of Medicine, St. Louis, Missouri, 63104, USA

    H. James Armbrecht Ph.D.

  4. Department of Community Medicine, St. Louis University School of Medicine, St. Louis, Missouri, 63104, USA

    Rodney M. Coe Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media New York

About this chapter

Cite this chapter

Strickler, R.C. (1990). Management of Female Menopause. In: Armbrecht, H.J., Coe, R.M., Wongsurawat, N. (eds) Endocrine Function and Aging. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3240-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-3240-7_10

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7930-3

  • Online ISBN: 978-1-4612-3240-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation